{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:59:06Z","timestamp":1743123546683,"version":"3.40.3"},"publisher-location":"Vienna","reference-count":198,"publisher":"Springer Vienna","isbn-type":[{"type":"print","value":"9783709116272"},{"type":"electronic","value":"9783709116289"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-7091-1628-9_14","type":"book-chapter","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T03:44:52Z","timestamp":1488167092000},"page":"139-156","source":"Crossref","is-referenced-by-count":0,"title":["Medical Treatment of Parkinson\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Anabela","family":"Valadas","sequence":"first","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"issue":"5","key":"14_CR1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427\u201342.","journal-title":"Neurology"},{"key":"14_CR2","first-page":"253","volume":"19","author":"MM Hoehn","year":"1983","unstructured":"Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neurol Transm Suppl. 1983;19:253\u201364.","journal-title":"J Neurol Transm Suppl"},{"issue":"2","key":"14_CR3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1600-0404.1977.tb01420.x","volume":"56","author":"RJ Marttila","year":"1977","unstructured":"Marttila RJ, Rinne UK. Disability and progression in Parkinson\u2019s disease. Acta Neurol Scand. 1977;56(2):159\u201369.","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"14_CR4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0733-8619(18)30213-5","volume":"10","author":"MM Hoehn","year":"1992","unstructured":"Hoehn MM. The natural history of Parkinson\u2019s disease in the pre-levodopa and post-levodopa eras. Neurol Clin. 1992;10(2):331\u20139.","journal-title":"Neurol Clin"},{"issue":"4917","key":"14_CR5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1126\/science.2502843","volume":"245","author":"JW Tetrud","year":"1989","unstructured":"Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson\u2019s disease. Science. 1989;245(4917):519\u201322.","journal-title":"Science"},{"issue":"6","key":"14_CR6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archneur.1972.00490180017005","volume":"27","author":"PH Stern","year":"1972","unstructured":"Stern PH, McDowell F, Miller JM, Robinson MB. Levodopa therapy effects on natural history of Parkinsonism. Arch Neurol. 1972;27(6):481\u20135.","journal-title":"Arch Neurol"},{"key":"14_CR7","first-page":"181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease. A clinico-pathological study of 100 cases. JNNP. 1992;55:181\u20134.","journal-title":"JNNP"},{"issue":"11 Suppl 5","key":"14_CR8","first-page":"S9","volume":"56","author":"CW Olanow","year":"2001","unstructured":"Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson\u2019s disease (2001): treatment guidelines. Neurology. 2001;56(11 Suppl 5):S9\u201329.","journal-title":"Neurology"},{"issue":"8","key":"14_CR9","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1212\/WNL.34.8.991","volume":"34","author":"AH Rajput","year":"1984","unstructured":"Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson\u2019s disease: an argument for delaying levodopa therapy. Neurology. 1984;34(8):991\u20136.","journal-title":"Neurology"},{"issue":"3 Suppl 1","key":"14_CR10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/ana.410440703","volume":"44","author":"WH Poewe","year":"1998","unstructured":"Poewe WH, Wenning GK. The natural history of Parkinson\u2019s disease. Ann Neurol. 1998;44(3 Suppl 1):S1\u20139.","journal-title":"Ann Neurol"},{"issue":"8","key":"14_CR11","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/jnnp.57.8.903","volume":"57","author":"MA Hely","year":"1994","unstructured":"Hely MA, Morris JG, Reid WG, O\u2019Sullivan DJ, Williamson PM, Rail D, Broe GA, Margrie S. The Sydney Multicentre Study of Parkinson\u2019s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry. 1994;57(8):903\u201310.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"14_CR12","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/jnnp.57.9.1034","volume":"57","author":"JL Montastruc","year":"1994","unstructured":"Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson\u2019s disease: a five year follow up. J Neurol Neurosurg Psychiatry. 1994;57(9):1034\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"14_CR13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0404.1996.tb00163.x","volume":"93","author":"E Dupont","year":"1996","unstructured":"Dupont E, Andersen A, Boas J, Boisen E, Borgmann R, Helgetveit AC, Kjaer MO, Kristensen TN, Mikkelsen B, Pakkenberg H, Presthus J, Stien R, Worm-Petersen J, Buch D. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand. 1996;93(1):14\u201320.","journal-title":"Acta Neurol Scand"},{"issue":"15","key":"14_CR14","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","volume":"284","author":"Parkinson Study Group","year":"2000","unstructured":"Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA. 2000;284(15):1931\u20138.","journal-title":"JAMA"},{"issue":"3","key":"14_CR15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ana.410430309","volume":"43","author":"Parkinson Study Group","year":"1998","unstructured":"Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson\u2019s disease. Ann Neurol. 1998;43(3):318\u201325.","journal-title":"Ann Neurol"},{"issue":"1","key":"14_CR16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ana.410390107","volume":"39","author":"Parkinson Study Group","year":"1996","unstructured":"Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson\u2019s disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol. 1996;39(1):37\u201345.","journal-title":"Ann Neurol"},{"issue":"3","key":"14_CR17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199301213280305","volume":"328","author":"Parkinson Study Group","year":"1993","unstructured":"Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson\u2019s disease. N Engl J Med. 1993;328(3):176\u201383.","journal-title":"N Engl J Med"},{"issue":"10","key":"14_CR18","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","volume":"46","author":"Parkinson Study Group","year":"1989","unstructured":"Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson\u2019s disease. Arch Neurol. 1989;46(10):1052\u201360.","journal-title":"Arch Neurol"},{"issue":"5","key":"14_CR19","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.53.5.1012","volume":"53","author":"WC Koller","year":"1999","unstructured":"Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa\/levodopa in PD: a 5-year randomized multicenter study. Carbidopa\/Levodopa Study Group. Neurology. 1999;53(5):1012\u20139.","journal-title":"Neurology"},{"issue":"3","key":"14_CR20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.60.3.387","volume":"60","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristic of dementia in Parkinson disease: an 8-years prospective study. Arch Neurol. 2003;60(3):387\u201392.","journal-title":"Arch Neurol"},{"key":"14_CR21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/jnnp.55.7.566","volume":"55","author":"CA Biggins","year":"1992","unstructured":"Biggins CA, Boyd JL, Harrop FM, Madeley P, Mindham RH, Randall JL, Spokes EG. A controlled, longitudinal study of dementia in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1992;55:566\u201371.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"14_CR22","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/ana.10219","volume":"51","author":"G Levy","year":"2002","unstructured":"Levy G, Schupf N, Tang MX, Cote L, Alfaro B, Mejia H, Tern Y, Marder K. Combined effect of age and severity on the risk of dementia in Parkinson\u2019s disease. Ann Neurol. 2002;51(6):722\u20139.","journal-title":"Ann Neurol"},{"issue":"Suppl 3","key":"14_CR23","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.23829","volume":"26","author":"SH Fox","year":"2011","unstructured":"Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26 Suppl 3:S2\u201341.","journal-title":"Mov Disord"},{"issue":"1","key":"14_CR24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","volume":"20","author":"JJ Ferreira","year":"2013","unstructured":"Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Sch\u00fcpbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH. Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson\u2019s disease. Eur J Neurol. 2013;20(1):5\u201315.","journal-title":"Eur J Neurol"},{"issue":"3","key":"14_CR25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/archneur.62.3.378","volume":"62","author":"R Hilker","year":"2005","unstructured":"Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH, Rudolf J, Herholz K, Heiss WD. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005;62(3):38\u201382.","journal-title":"Arch Neurol"},{"key":"14_CR26","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/1531-8249(200006)47:6<804::AID-ANA14>3.0.CO;2-F","volume":"47","author":"E Nurmi","year":"2000","unstructured":"Nurmi E, Ruottinen H, Kaasinen V, Bergman J, Haaparanta M, Solin O, Rinne JO. Progression in Parkinson\u2019s disease: a positron emission tomography study with a dopamine transporter ligand [18F]CTF. Ann Neurol. 2000;47:804\u20138.","journal-title":"Ann Neurol"},{"issue":"3","key":"14_CR27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/jnnp.64.3.314","volume":"64","author":"PK Morrish","year":"1998","unstructured":"Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson\u2019s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64(3):314\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"14_CR28","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ana.410360512","volume":"36","author":"FJG Vingerhoets","year":"1994","unstructured":"Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic Parkinsonism. Ann Neurol. 1994;36:759\u201364.","journal-title":"Ann Neurol"},{"issue":"8","key":"14_CR29","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/01.WNL.0000058760.13152.1A","volume":"60","author":"BM Ravina","year":"2003","unstructured":"Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR. Neuroprotective agents for clinical trials in Parkinson\u2019s disease: a systematic assessment. Neurology. 2003;60(8):1234\u201340.","journal-title":"Neurology"},{"issue":"3","key":"14_CR30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jama.291.3.358","volume":"291","author":"AH Schapira","year":"2004","unstructured":"Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA. 2004;291(3):358\u201364.","journal-title":"JAMA"},{"issue":"7 Suppl 2","key":"14_CR31","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1212\/WNL.63.7_suppl_2.S23","volume":"63","author":"PA LeWitt","year":"2004","unstructured":"LeWitt PA. Clinical trials of neuroprotection for Parkinson\u2019s disease. Neurology. 2004;63(7 Suppl 2):S23\u201331.","journal-title":"Neurology"},{"issue":"5","key":"14_CR32","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/mds.22432","volume":"24","author":"RG Hart","year":"2009","unstructured":"Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection trials in Parkinson\u2019s disease: systematic review. Mov Disord. 2009;24(5):647\u201354.","journal-title":"Mov Disord"},{"issue":"7 Suppl 2","key":"14_CR33","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1212\/WNL.63.7_suppl_2.S13","volume":"63","author":"P Jenner","year":"2004","unstructured":"Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson\u2019s disease. Neurology. 2004;63(7 Suppl 2):S13\u201322.","journal-title":"Neurology"},{"issue":"4","key":"14_CR34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","volume":"61","author":"Parkinson Study Group","year":"2004","unstructured":"Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61(4):561\u20136.","journal-title":"Arch Neurol"},{"issue":"13","key":"14_CR35","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E, ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med. 2009;361(13):1268\u201378.","journal-title":"N Engl J Med"},{"issue":"14","key":"14_CR36","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.0b013e3181d7d8e2","volume":"74","author":"JE Ahlskog","year":"2010","unstructured":"Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology. 2010;74(14):1143\u20138.","journal-title":"Neurology"},{"issue":"15","key":"14_CR37","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1212\/WNL.0b013e3181a0feba","volume":"72","author":"PA Lewitt","year":"2009","unstructured":"Lewitt PA. MAO-B inhibitor know-how: back to the pharm. Neurology. 2009;72(15):1352\u20137.","journal-title":"Neurology"},{"issue":"5","key":"14_CR38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1474-4422(11)70073-4","volume":"10","author":"O Rascol","year":"2011","unstructured":"Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW. A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10(5):415\u201323.","journal-title":"Lancet Neurol"},{"issue":"10","key":"14_CR39","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","volume":"59","author":"CW Shults","year":"2002","unstructured":"Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M, Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541\u201350.","journal-title":"Arch Neurol"},{"issue":"8","key":"14_CR40","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/archneur.60.8.1170-b","volume":"60","author":"MW Horstink","year":"2003","unstructured":"Horstink MW, van Engelen BG. The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic. Arch Neurol. 2003;60(8):1170\u20132.","journal-title":"Arch Neurol"},{"issue":"7","key":"14_CR41","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneur.64.7.nct60005","volume":"64","author":"A Storch","year":"2007","unstructured":"Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, M\u00fcller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H, German Coenzyme Q(10) Study Group. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. 2007;64(7):938\u201344.","journal-title":"Arch Neurol"},{"key":"14_CR42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","volume":"71","author":"MF Beal","year":"2014","unstructured":"Beal MF, Oakes D, Shoulson I, Parkinson Study Group QE3 Investigators. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71:543\u201352.","journal-title":"JAMA Neurol"},{"key":"14_CR43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2051-5960-1-2","volume":"1","author":"NP Visanji","year":"2013","unstructured":"Visanji NP, Brooks PL, Hazrati L-N, Lange AE. The prion hypothesis in Parkinson\u2019s disease: Braak to the future. Acta Neuropathol Commun. 2013;1:2.","journal-title":"Acta Neuropathol Commun"},{"key":"14_CR44","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0b013e318263570d","volume":"79","author":"RB Postuma","year":"2012","unstructured":"Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, Filla L, Zanatta D, Rios Romenets S, Altman R, Shah B. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology. 2012;79:651\u20138.","journal-title":"Neurology"},{"key":"14_CR45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","volume":"59","author":"AE Lang","year":"2016","unstructured":"Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VG, Elias WJ, Laws ER, Dhawan V, Stoessl AJ, Matcham J, Coffey RJ, Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2016;59:459\u201366.","journal-title":"Ann Neurol"},{"key":"14_CR46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","volume":"276","author":"GC Cotzias","year":"1967","unstructured":"Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276:374\u20139.","journal-title":"N Engl J Med"},{"key":"14_CR47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","volume":"280","author":"GC Cotzias","year":"1969","unstructured":"Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism-chronic treatment with L-dopa. N Engl J Med. 1969;280:337\u201345.","journal-title":"N Engl J Med"},{"issue":"2","key":"14_CR48","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0022-510X(91)90046-A","volume":"101","author":"M Tanaka","year":"1991","unstructured":"Tanaka M, Sotomatsu A, Kanai H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci. 1991;101(2):198\u2013203.","journal-title":"J Neurol Sci"},{"issue":"9","key":"14_CR49","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/mds.20243","volume":"19","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F. Levodopa in the treatment of Parkinson\u2019s disease: current controversies. Mov Disord. 2004;19(9):997\u20131005.","journal-title":"Mov Disord"},{"issue":"5","key":"14_CR50","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ana.410250521","volume":"25","author":"MM Mouradian","year":"1989","unstructured":"Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson\u2019s disease. Ann Neurol. 1989;25(5):523\u20136.","journal-title":"Ann Neurol"},{"issue":"24","key":"14_CR51","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group. Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med. 2004;351(24):2498\u2013508.","journal-title":"N Engl J Med"},{"issue":"1","key":"14_CR52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW. Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18\u201327.","journal-title":"Ann Neurol"},{"issue":"6 Suppl 6","key":"14_CR53","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1212\/WNL.50.6_Suppl_6.S15","volume":"50","author":"R Capildeo","year":"1998","unstructured":"Capildeo R. Implications of the 5-year CR FIRST trial. Sinemet CR Five-Year International Response Fluctuation Study. Neurology. 1998;50(6 Suppl 6):S15\u20137. discussion S44\u2013S48.","journal-title":"Neurology"},{"issue":"1","key":"14_CR54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med. 2007;356(1):39\u201346.","journal-title":"N Engl J Med"},{"key":"14_CR55","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/WNL.53.2.364","volume":"53","author":"AD Korczyn","year":"1999","unstructured":"Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson\u2019s disease. The 053 Study Group. Neurology. 1999;53:364\u201370.","journal-title":"Neurology"},{"key":"14_CR56","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.33.8.1009","volume":"33","author":"PA LeWitt","year":"1983","unstructured":"LeWitt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, Foster N, Dambrosia JM, Calne DB. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology. 1983;33:1009\u201314.","journal-title":"Neurology"},{"key":"14_CR57","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mds.870090409","volume":"9","author":"G Pezzoli","year":"1994","unstructured":"Pezzoli G, Martignoni E, Pacchetti C, Angeleri VA, Lamberti P, Muratorio A, De Mari M, Foschi N, Cossutta E, et al. Pergolide compared with bromocriptine in Parkinson\u2019s disease: a multicenter, crossover, controlled study. Mov Disord. 1994;9:431\u20136.","journal-title":"Mov Disord"},{"key":"14_CR58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mds.870130112","volume":"13","author":"AD Korczyn","year":"1998","unstructured":"Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson\u2019s disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord. 1998;13:46\u20138.","journal-title":"Mov Disord"},{"key":"14_CR59","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.53.3.573","volume":"53","author":"P Barone","year":"1999","unstructured":"Barone P, Bravi D, Bermejo-Pareja F, Marconi R, Kulisevsky J, Malag\u00f9 S, Weiser R, Rost N. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology. 1999;53:573.","journal-title":"Neurology"},{"key":"14_CR60","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00002826-199508000-00006","volume":"18","author":"JP Hubble","year":"1995","unstructured":"Hubble JP, Koller WC, Cutler NR, Sramek JJ, Friedman J, Goetz C, Ranhosky A, Korts D, Elvin A. Pramipexole in patients with early Parkinson\u2019s disease. Clin Neuropharmacol. 1995;18:338\u201347.","journal-title":"Clin Neuropharmacol"},{"key":"14_CR61","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1212\/WNL.49.2.393","volume":"49","author":"CH Adler","year":"1997","unstructured":"Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O\u2019Brien CF. Ropinirole for the treatment of early Parkinson\u2019s disease. The Ropinirole Study Group. Neurology. 1997;49:393\u20139.","journal-title":"Neurology"},{"key":"14_CR62","first-page":"CD006564","volume":"2","author":"RL Stowe","year":"2008","unstructured":"Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, Shah L, Wheatley K, Gray R. Dopamine agonist therapy in early Parkinson\u2019s disease. Cochrane Database Syst Rev. 2008;2:CD006564.","journal-title":"Cochrane Database Syst Rev"},{"key":"14_CR63","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000;342:1484\u201391.","journal-title":"N Engl J Med"},{"key":"14_CR64","first-page":"1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Parkinson Study Group, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044\u201353.","journal-title":"Arch Neurol"},{"issue":"10","key":"14_CR65","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1185\/03007990802387130","volume":"24","author":"F Stocchi","year":"2008","unstructured":"Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson\u2019s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008;24(10):2883\u201395.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"14_CR66","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1212\/WNL.0b013e31822affb0","volume":"77","author":"W Poewe","year":"2011","unstructured":"Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH, Pramipexole ER Studies Group. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011;77(8):759\u201366.","journal-title":"Neurology"},{"issue":"4","key":"14_CR67","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","volume":"68","author":"RL Watts","year":"2007","unstructured":"Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68(4):272\u20136.","journal-title":"Neurology"},{"issue":"1","key":"14_CR68","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/2047-783X-18-60","volume":"18","author":"C Pellicano","year":"2013","unstructured":"Pellicano C, Benincasa D, Fanciulli A, Latino P, Giovannelli M, Pontieri FE. The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson\u2019s disease: an observational study. Eur J Med Res. 2013;18(1):60\u20135.","journal-title":"Eur J Med Res"},{"issue":"8","key":"14_CR69","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5(8):677\u201387.","journal-title":"Lancet Neurol"},{"key":"14_CR70","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00702-013-1008-y","volume":"120","author":"C Ossig","year":"2013","unstructured":"Ossig C, Reichmann H. Treatment of Parkinson\u2019s disease in the advanced stage. J Neural Transm. 2013;120:523\u20139.","journal-title":"J Neural Transm"},{"issue":"4","key":"14_CR71","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","volume":"12","author":"RA Hauser","year":"2013","unstructured":"Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, Ondo W, O\u2019Connell M, Gupta S, IPX066 ADVANCE-PD Investigators. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson\u2019s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346\u201356.","journal-title":"Lancet Neurol"},{"key":"14_CR72","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.parkreldis.2014.08.004","volume":"20","author":"F Stocchi","year":"2014","unstructured":"Stocchi F, Hsu A, Kell S, Ellenbogen A, Mahler A, Liang G, Dillmann U, Rubens R, Kell S, Gupta S. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014;20:1335\u201340.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"14_CR73","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mds.870090107","volume":"9","author":"CW Olanow","year":"1994","unstructured":"Olanow CW, Fanh S, Muenter M, Klawans H, Hurtig H, Stern M, Shoulson I, Kurlan R, Grimes JD, Jankovic, et al. A multicenter double-blinde placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson\u2019s disease. Mov Disord. 1994;9(1):40\u20137.","journal-title":"Mov Disord"},{"issue":"3","key":"14_CR74","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00002826-199619030-00005","volume":"19","author":"O Rascol","year":"1996","unstructured":"Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson\u2019s disease. Clin Neuropharmacol. 1996;19(3):234\u201345.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"14_CR75","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.49.1.162","volume":"49","author":"A Lieberman","year":"1997","unstructured":"Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson\u2019s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49(1):162\u20138.","journal-title":"Neurology"},{"issue":"4","key":"14_CR76","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","volume":"51","author":"A Lieberman","year":"1998","unstructured":"Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, Hurtig H, Yahr M. A multicenter trial of ropinirole as adjunct treatment for Parkinson\u2019s disease. Ropinirole Study Group. Neurology. 1998;51(4):1057\u201362.","journal-title":"Neurology"},{"issue":"14","key":"14_CR77","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","volume":"68","author":"R Pahwa","year":"2007","unstructured":"Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108\u201315.","journal-title":"Neurology"},{"issue":"16","key":"14_CR78","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","volume":"68","author":"PA LeWitt","year":"2007","unstructured":"LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68(16):1262\u20137.","journal-title":"Neurology"},{"issue":"8","key":"14_CR79","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1212\/WNL.0b013e31822affdb","volume":"77","author":"AH Schapira","year":"2011","unstructured":"Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin N, Poewe W, Pramipexole ER Studies Group. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011;77(8):767\u201374.","journal-title":"Neurology"},{"issue":"4","key":"14_CR80","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1212\/WNL.49.4.1060","volume":"49","author":"M Guttman","year":"1997","unstructured":"Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson\u2019s disease. International Pramipexole-Bromocriptine Study Group. Neurology. 1997;49(4):1060\u20135.","journal-title":"Neurology"},{"key":"14_CR81","doi-asserted-by":"crossref","unstructured":"Clarke CE, Deane KD. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson\u2019s disease. Cochrane Database Syst Rev. 2001;1:CD001519. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B; SP 515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513\u201320.","DOI":"10.1002\/14651858.CD001519"},{"key":"14_CR82","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","volume":"58","author":"RB Dewey Jr","year":"2001","unstructured":"Dewey Jr RB, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:1385\u201392.","journal-title":"Arch Neurol"},{"issue":"9111","key":"14_CR83","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(05)79311-9","volume":"351","author":"JG Nutt","year":"1998","unstructured":"Nutt JG. Catechol-O-methyltransferase inhibitors for treatment of Parkinson\u2019s disease. Lancet. 1998;351(9111):1221\u20132.","journal-title":"Lancet"},{"issue":"4","key":"14_CR84","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.49.4.1066","volume":"49","author":"AH Rajput","year":"1997","unstructured":"Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the \u201cwearing-off\u201d phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology. 1997;49(4):1066\u201371.","journal-title":"Neurology"},{"issue":"4","key":"14_CR85","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jnnp.63.4.421","volume":"63","author":"H Baas","year":"1997","unstructured":"Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayer G. Catechol-O-methyltransferase inhibition with tolcapone reduces the \u201cwearing off\u201d phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997;63(4):421\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"14_CR86","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","volume":"42","author":"Parkinson Study Group","year":"1997","unstructured":"Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson\u2019s disease patients. Ann Neurol. 1997;42(5):747\u201355.","journal-title":"Ann Neurol"},{"issue":"11 Suppl 4","key":"14_CR87","first-page":"S51","volume":"55","author":"P Watkins","year":"2000","unstructured":"Watkins P. COMT inhibitors and liver toxicity. Neurology. 2000;55(11 Suppl 4):S51\u20132.","journal-title":"Neurology"},{"key":"14_CR88","first-page":"CD004554","volume":"4","author":"KH Deane","year":"2004","unstructured":"Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson\u2019s disease. Cochrane Database Syst Rev. 2004;4:CD004554.","journal-title":"Cochrane Database Syst Rev"},{"key":"14_CR89","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 Investigators. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2015 Dec 22. pii: S1474-4422(15)00336-1."},{"issue":"9463","key":"14_CR90","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, LARGO Study Group. Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trial. Lancet. 2005;365(9463):947\u201354.","journal-title":"Lancet"},{"key":"14_CR91","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, Study 016 Investigators. Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord. 2014;29:229\u201337.","journal-title":"Mov Disord"},{"key":"14_CR92","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, Study 018 Investigators. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov Disord. 2014;29:1273\u201380.","journal-title":"Mov Disord"},{"key":"14_CR93","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJM198402233100802","volume":"310","author":"JG Nutt","year":"1984","unstructured":"Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The \u201con-off\u201d phenomenon in Parkinson\u2019s disease. Relation to levodopa absorption and transport. N Engl J Med. 1984;310:483\u20138.","journal-title":"N Engl J Med"},{"key":"14_CR94","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/archneur.1992.00530260049018","volume":"49","author":"PJ Karstaedt","year":"1992","unstructured":"Karstaedt PJ, Pincus JH. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol. 1992;49:149\u201351.","journal-title":"Arch Neurol"},{"key":"14_CR95","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1212\/WNL.38.7.1026","volume":"38","author":"D Riley","year":"1988","unstructured":"Riley D, Lang AE. Practical application of a low-protein diet for Parkinson\u2019s disease. Neurology. 1988;38:1026\u201331.","journal-title":"Neurology"},{"issue":"6","key":"14_CR96","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/mds.870120618","volume":"12","author":"I SoyKan","year":"1997","unstructured":"SoyKan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson\u2019s disease. Mov Disord. 1997;12(6):952\u20137.","journal-title":"Mov Disord"},{"issue":"4","key":"14_CR97","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00002512-199710040-00002","volume":"10","author":"WH Jost","year":"1997","unstructured":"Jost WH. Gastrointestinal motility problems in patients with Parkinson\u2019s disease. Effects of antiparkinsonian treatment and guidelines for management. Drugs Aging. 1997;10(4):249\u201358.","journal-title":"Drugs Aging"},{"issue":"16","key":"14_CR98","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1161\/01.CIR.102.16.1883","volume":"102","author":"B Drolet","year":"2000","unstructured":"Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation. 2000;102(16):1883\u20135.","journal-title":"Circulation"},{"issue":"3","key":"14_CR99","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448\u201358.","journal-title":"Mov Disord"},{"issue":"2","key":"14_CR100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","volume":"23","author":"BJ Snow","year":"2000","unstructured":"Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on L-dopa-induced dyskinesias in Parkinson\u2019s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000;23(2):82\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"11","key":"14_CR101","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","volume":"56","author":"LV Metman","year":"1999","unstructured":"Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999;56(11):1383\u20136.","journal-title":"Arch Neurol"},{"issue":"3","key":"14_CR102","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1212\/WNL.48.3.658","volume":"48","author":"F Durif","year":"1997","unstructured":"Durif F, Vidailhet M, Assal F, Roche C, Bonnet AM, Agid Y. Low-dose clozapine improves dyskinesias in Parkinson\u2019s disease. Neurology. 1997;48(3):658\u201362.","journal-title":"Neurology"},{"issue":"8","key":"14_CR103","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.43.8.1551","volume":"43","author":"JP Bennet","year":"1993","unstructured":"Bennet JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinso\u2019s disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology. 1993;43(8):1551\u20135.","journal-title":"Neurology"},{"issue":"3","key":"14_CR104","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","volume":"62","author":"F Durif","year":"2004","unstructured":"Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, Rascol O. Clozapine improves dyskinesias in Parkinson\u2019s disease: a double-blind, placebo-controlled study. Neurology. 2004;62(3):381\u20138.","journal-title":"Neurology"},{"issue":"6","key":"14_CR105","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.55.6.795","volume":"55","author":"AJ Manson","year":"2000","unstructured":"Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology. 2000;55(6):795\u20139.","journal-title":"Neurology"},{"issue":"4","key":"14_CR106","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/WCO.0b013e3283542fc2","volume":"25","author":"J Jankovic","year":"2012","unstructured":"Jankovic J, Poewe W. Therapies in Parkinson\u2019s disease. Curr Opin Neurol. 2012;25(4):433\u201347.","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"14_CR107","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00702-010-0555-8","volume":"118","author":"R Hilker","year":"2011","unstructured":"Hilker R, Antonini A, Odin P. What is the best treatment for fluctuating Parkinson\u2019s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? J Neural Transm. 2011;118(6):907\u201314.","journal-title":"J Neural Transm"},{"issue":"3","key":"14_CR108","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-199937030-00004","volume":"37","author":"C Neef","year":"1999","unstructured":"Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson\u2019s disease. Clin Pharmacokinet. 1999;37(3):257\u201371.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"14_CR109","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/mds.22596","volume":"24","author":"H Honig","year":"2009","unstructured":"Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR. Intrajejunal levodopa infusion in Parkinson\u2019s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24(10):1468\u201374.","journal-title":"Mov Disord"},{"issue":"3\u20134","key":"14_CR110","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000113714","volume":"5","author":"A Antonini","year":"2008","unstructured":"Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L, Pacchetti C, Zibetti M, Natuzzi F, Lopiano L, Nappi G, Pezzoli G. Duodenal levodopa infusion improves quality of live in advanced Parkinson\u2019s disease. Neurodegener Dis. 2008;5(3\u20134):244\u20136.","journal-title":"Neurodegener Dis"},{"key":"14_CR111","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.archger.2004.04.039","volume":"9","author":"L Morgante","year":"2004","unstructured":"Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F, Di Rosa AE. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson \u2019s disease: a follow-up of two years. Arch Gerontol Geriatr Suppl. 2004;9:291\u20136.","journal-title":"Arch Gerontol Geriatr Suppl"},{"issue":"6 Suppl 4","key":"14_CR112","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1212\/WNL.62.6_suppl_4.S32","volume":"62","author":"A Bowron","year":"2004","unstructured":"Bowron A. Practical considerations in the use of apomorphine injectable. Neurology. 2004;62(6 Suppl 4):S32\u20136.","journal-title":"Neurology"},{"issue":"3","key":"14_CR113","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/wnf.0b013e31814b113e","volume":"31","author":"K Eggert","year":"2008","unstructured":"Eggert K, Schrader C, Hahn M, Stamelou M, Russmann A, Dengler R, Oertel W, Odin P. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor of motor and non-motor complications. Clin Neuropharmacol. 2008;31(3):151\u201366.","journal-title":"Clin Neuropharmacol"},{"key":"14_CR114","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/mds.26362","volume":"30","author":"O Rascol","year":"2015","unstructured":"Rascol O, Perez-Lloret S, Ferreira JJ. New treatments for levodopa-induced motor complications. Mov Disord. 2015;30:1451\u201360.","journal-title":"Mov Disord"},{"key":"14_CR115","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1474-4422(12)70152-7","volume":"11","author":"P Svenningsson","year":"2012","unstructured":"Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson\u2019s disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11:697\u2013707.","journal-title":"Lancet Neurol"},{"key":"14_CR116","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.20527","volume":"20","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson\u2019s disease. Mov Discord. 2005;20:1255\u201363.","journal-title":"Mov Discord"},{"key":"14_CR117","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/01.wnl.0000180516.69442.95","volume":"65","author":"D Muslimovic","year":"2005","unstructured":"Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65:1239\u201345.","journal-title":"Neurology"},{"key":"14_CR118","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1212\/WNL.41.3.365","volume":"41","author":"BE Levin","year":"1991","unstructured":"Levin BE, Llabre MM, Reisman S, Weiner WJ, Sanchez-Ramos J, Singer C, Brown MC. Visual impairment in Parkinson\u2019s disease. Neurology. 1991;41:365\u20139.","journal-title":"Neurology"},{"key":"14_CR119","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1212\/01.wnl.0000306632.43729.24","volume":"70","author":"TC Butter","year":"2008","unstructured":"Butter TC, van der Hout A, Mattheus FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson\u2019s disease: a 12-year population study. Neurology. 2008;70:1017\u201322.","journal-title":"Neurology"},{"key":"14_CR120","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R. Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med. 2004;351:2509\u201318.","journal-title":"N Engl J Med"},{"key":"14_CR121","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","volume":"68","author":"D Aarsland","year":"2002","unstructured":"Aarsland D, Laake K, Larsen J, Javin C. Donepezil for cognitive impairment in Parkinson\u2019s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;68:708\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"14_CR122","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","volume":"76","author":"B Ravina","year":"2005","unstructured":"Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T. Donepezil for dementia in Parkinson\u2019s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:934\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"14_CR123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gps.993","volume":"19","author":"I Leroi","year":"2004","unstructured":"Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson\u2019s disease. Int J Geriatr Psychiatry. 2004;19:1\u20138.","journal-title":"Int J Geriatr Psychiatry"},{"key":"14_CR124","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s11055-008-9077-3","volume":"38","author":"I Litvinenko","year":"2008","unstructured":"Litvinenko I, Odinak M, Mogil\u2019naya V, Emelin A. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson\u2019s disease (an open controlled trial). Neurosci Behav Physiol. 2008;38:937\u201345.","journal-title":"Neurosci Behav Physiol"},{"key":"14_CR125","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","volume":"8","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E. Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8:613\u20138.","journal-title":"Lancet Neurol"},{"key":"14_CR126","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","volume":"9","author":"M Emre","year":"2010","unstructured":"Emre M, Tsolaki M, Bonuccelli U, Dest\u00e9e A, Tolosa E, Kutzelnigg A, Ceballos-Baumann A, Zdravkovic S, Bladstr\u00f6m A, Jones R, 11018 Study Investigators. Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomized double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:969\u201377.","journal-title":"Lancet Neurol"},{"key":"14_CR127","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/mds.22495","volume":"24","author":"I Leroi","year":"2009","unstructured":"Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson\u2019s disease. Mov Disord. 2009;24:1217\u201321.","journal-title":"Mov Disord"},{"issue":"9","key":"14_CR128","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.parkreldis.2010.05.004","volume":"16","author":"JH Friedman","year":"2010","unstructured":"Friedman JH. Parkinson\u2019s disease psychosis 2010: a review article. Parkinsonism Relat Disord. 2010;16(9):553\u201360.","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"14_CR129","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","volume":"67","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, Alves G. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996\u20131001.","journal-title":"Arch Neurol"},{"issue":"8","key":"14_CR130","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","volume":"25","author":"LB Zahodne","year":"2008","unstructured":"Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson\u2019s disease: a review. Drugs Aging. 2008;25(8):665\u201382.","journal-title":"Drugs Aging"},{"issue":"11","key":"14_CR131","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","volume":"21","author":"D Burn","year":"2006","unstructured":"Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson\u2019s disease. Mov Disord. 2006;21(11):1899\u2013907.","journal-title":"Mov Disord"},{"key":"14_CR132","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"Parkinson Study Group","year":"1999","unstructured":"Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med. 1999;340:757\u201363.","journal-title":"N Engl J Med"},{"key":"14_CR133","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q","volume":"16","author":"SA Factor","year":"2001","unstructured":"Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K, Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord. 2001;16:135\u20139.","journal-title":"Mov Disord"},{"key":"14_CR134","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak P, Tison F, Rascol O, Dest\u00e9e A, P\u00e9r\u00e9 JJ, Senard JM, Durif F, Bourdeix I. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75:689\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"14_CR135","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1345\/aph.1G396","volume":"40","author":"P Schulte","year":"2006","unstructured":"Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother. 2006;40:683\u20138.","journal-title":"Ann Pharmacother"},{"key":"14_CR136","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/1531-8257(199905)14:3<484::AID-MDS1016>3.0.CO;2-B","volume":"14","author":"HH Fernandez","year":"1999","unstructured":"Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. Mov Disord. 1999;14:484\u20137.","journal-title":"Mov Disord"},{"issue":"Supl 2","key":"14_CR137","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1007\/s100720200084","volume":"23","author":"L Morgante","year":"2002","unstructured":"Morgante L, Epifanio A, Spina E, Di Rosa AE, Zappia M, Basile G, La Spina P, Quattrone A. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson\u2019s disease. Neurol Sci. 2002;23(Supl 2):S89\u201390.","journal-title":"Neurol Sci"},{"key":"14_CR138","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/mds.10620","volume":"19","author":"JL Juncos","year":"2004","unstructured":"Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, Jou HC, Yeung PP. Quetiapine improves psychotic symptoms and cognition in Parkinson\u2019s disease. Mov Disord. 2004;19:29\u201335.","journal-title":"Mov Disord"},{"key":"14_CR139","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285610389656","volume":"3","author":"P Shotbolt","year":"2010","unstructured":"Shotbolt P, Samuel M, David A. Quetiapine in the treatment of psychosis in Parkinson\u2019s disease. Ther Adv Neurol Disord. 2010;3:339\u201350.","journal-title":"Ther Adv Neurol Disord"},{"key":"14_CR140","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","volume":"52","author":"A Breier","year":"2002","unstructured":"Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease. Biol Psychiatry. 2002;52:438\u201345.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"14_CR141","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","volume":"55","author":"C Goetz","year":"2000","unstructured":"Goetz C, Blasucci L, Leurgans S, Pappert E. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55(6):789\u201394.","journal-title":"Neurology"},{"issue":"6","key":"14_CR142","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9","volume":"15","author":"E Mohr","year":"2000","unstructured":"Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson\u2019s disease: an open pilot trial. Mov Disord. 2000;15(6):1230\u20137.","journal-title":"Mov Disord"},{"issue":"8909","key":"14_CR143","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0140-6736(94)92511-9","volume":"343","author":"G Meco","year":"1994","unstructured":"Meco G, Alessandria A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated in Parkinson\u2019s disease patients. Lancet. 1994;343(8909):1370\u20131.","journal-title":"Lancet"},{"issue":"9916","key":"14_CR144","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340.","journal-title":"Lancet"},{"issue":"4","key":"14_CR145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1176\/ajp.149.4.443","volume":"149","author":"JL Cummings","year":"1992","unstructured":"Cummings JL. Depression and Parkinson\u2019s disease: a review. Am J Psychiatry. 1992;149(4):443\u201354.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"14_CR146","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mds.10114","volume":"17","author":"DJ Burn","year":"2002","unstructured":"Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson\u2019s disease. Mov Disord. 2002;17(3):445\u201354.","journal-title":"Mov Disord"},{"issue":"7","key":"14_CR147","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","volume":"66","author":"JM Miyasaki","year":"2006","unstructured":"Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson\u2019s disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996\u20131002.","journal-title":"Neurology"},{"key":"14_CR148","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0404.1980.tb03028.x","volume":"62","author":"J Andersen","year":"1980","unstructured":"Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Antidepressive treatment in Parkinson\u2019s disease: a controlled trial of the effect of nortriptyline in patients with Parkinson\u2019s disease treated with L-dopa. Acta Neurol Scand. 1980;62:210\u20139.","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"14_CR149","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","volume":"72","author":"M Menza","year":"2009","unstructured":"Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72(10):886\u201392.","journal-title":"Neurology"},{"issue":"16","key":"14_CR150","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","volume":"78","author":"IH Richard","year":"2012","unstructured":"Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W, SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78(16):1229\u201336.","journal-title":"Neurology"},{"issue":"6","key":"14_CR151","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/gps.865","volume":"18","author":"AF Leentjens","year":"2003","unstructured":"Leentjens AF, Vreeling FW, Luijeckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson\u2019s disease. Int J Geriatr Psychiatry. 2003;18(6):552\u20134.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"8","key":"14_CR152","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1212\/WNL.55.8.1216","volume":"55","author":"R Ceravolo","year":"2000","unstructured":"Ceravolo R, Nuti A, Piccinni A, Dell\u2019Agnello G, Bellini G, Gambaccini G, Dell\u2019Osso L, Murri L, Bonuccelli U. Paroxetine in Parkinson\u2019s disease: effects on motor and depressive symptoms. Neurology. 2000;55(8):1216\u20138.","journal-title":"Neurology"},{"issue":"10","key":"14_CR153","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4088\/JCP.v57n1002","volume":"57","author":"RJ Leo","year":"1996","unstructured":"Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57(10):449\u201354.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"14_CR154","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.48.4.1070","volume":"48","author":"IH Richard","year":"1997","unstructured":"Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson\u2019s disease. Parkinson Study Group. Neurology. 1997;48(4):1070\u20137.","journal-title":"Neurology"},{"issue":"6","key":"14_CR155","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573\u201380.","journal-title":"Lancet Neurol"},{"issue":"11","key":"14_CR156","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/mds.21428","volume":"22","author":"KL Scoffer","year":"2007","unstructured":"Scoffer KL, Henderson RD, O\u2019Maley K, O\u2019Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson\u2019s disease. Mov Disord. 2007;22(11):1543\u20139.","journal-title":"Mov Disord"},{"key":"14_CR157","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0002-9343(93)90230-M","volume":"95","author":"J Jankovic","year":"1993","unstructured":"Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM. Neurogenic orthostatic hypotension: a double-blind placebo-controlled study with midodrine. Am J Med. 1993;95:38\u201348.","journal-title":"Am J Med"},{"key":"14_CR158","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.1997.03540370036033","volume":"277","author":"PA Low","year":"1997","unstructured":"Low PA, Gilden FL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized double-blind multicenter study. Midodrine study group. JAMA. 1997;277:1046\u201351.","journal-title":"JAMA"},{"key":"14_CR159","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archneur.1975.00490430072013","volume":"32","author":"MM Hoehn","year":"1975","unstructured":"Hoehn MM. Levodopa induced postural hypotension. Treatment with fludrocortisone. Arch Neurol. 1975;32:50\u20131.","journal-title":"Arch Neurol"},{"key":"14_CR160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11940-000-0005-2","volume":"2","author":"DE Riley","year":"2000","unstructured":"Riley DE. Orthostatic hypotension in multiple system atrophy. Curr Treat Options Neurol. 2000;2:225\u201330.","journal-title":"Curr Treat Options Neurol"},{"key":"14_CR161","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/mds.26179","volume":"5","author":"SH Fox","year":"2015","unstructured":"Fox SH, Marras C. Orthostatic hypotension in Parkinsonism: what is it and how can we treat it? Mov Disord. 2015;5:601\u20133.","journal-title":"Mov Disord"},{"key":"14_CR162","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000116810","volume":"32","author":"C Singer","year":"1992","unstructured":"Singer C, Weiner W, Sanchez-Ramos J. Autonomic dysfunction in men with Parkinson\u2019s disease. Eur Neurol. 1992;32:134\u201340.","journal-title":"Eur Neurol"},{"key":"14_CR163","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/mds.870100318","volume":"10","author":"O Suchowersky","year":"1995","unstructured":"Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson\u2019s disease. Mov Disord. 1995;10:337\u201340.","journal-title":"Mov Disord"},{"issue":"3","key":"14_CR164","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00002512-199506030-00007","volume":"6","author":"YE Yarker","year":"1995","unstructured":"Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacokinetic properties and its therapeutic use in detrusor instability. Drugs Aging. 1995;6(3):243\u201362.","journal-title":"Drugs Aging"},{"key":"14_CR165","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","volume":"50","author":"RA Appell","year":"1997","unstructured":"Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology. 1997;50:90\u20136.","journal-title":"Urology"},{"key":"14_CR166","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(88)90932-4","volume":"2","author":"TJ Christmas","year":"1988","unstructured":"Christmas TJ, Kempster PA, Chapple CR, Frankel JP, Lees AJ, Stern GM, Milroy EJ. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet. 1988;2:1451\u20133.","journal-title":"Lancet"},{"key":"14_CR167","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004836-199407000-00004","volume":"19","author":"C Byrne","year":"1994","unstructured":"Byrne C, Pfeiffer R, Quigley EM. Gastrointestinal dysfunction in Parkinson\u2019s disease: a report of clinical experience at a single center. J Clin Gastroenterol. 1994;19:11\u20136.","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"14_CR168","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/mds.21243","volume":"22","author":"R Zangaglia","year":"2007","unstructured":"Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, Brunetti G, Pacchetti C. Macrogol for the treatment of constipation in Parkinson\u2019s disease. A randomized placebo-controlled study. Mov Disord. 2007;22(9):1239\u201344.","journal-title":"Mov Disord"},{"issue":"1","key":"14_CR169","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mds.20666","volume":"21","author":"KL Sullivan","year":"2006","unstructured":"Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson\u2019s disease. Mov Disord. 2006;21(1):115\u20136.","journal-title":"Mov Disord"},{"issue":"11","key":"14_CR170","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/archinte.1989.00390110070015","volume":"149","author":"LG Miller","year":"1989","unstructured":"Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med. 1989;149(11):2486\u201392.","journal-title":"Arch Intern Med"},{"issue":"12","key":"14_CR171","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archinte.1993.00410120051007","volume":"153","author":"L Ganzini","year":"1993","unstructured":"Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993;153(12):1469\u201375.","journal-title":"Arch Intern Med"},{"issue":"15","key":"14_CR172","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1212\/WNL.0b013e3181d8c1b7","volume":"74","author":"ME Arbouw","year":"2010","unstructured":"Arbouw ME, Movig KL, Koopmann M, Poels PJ, Guchelaar HJ, Egberts TC, Neef C, van Vugt JP. Glycopyrrolate for sialorrhea in Parkinson\u2019s disease: a randomized, double-blind, crossover trial. Neurology. 2010;74(15):1203\u20137.","journal-title":"Neurology"},{"issue":"6","key":"14_CR173","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/mds.10276","volume":"17","author":"HC Hyson","year":"2002","unstructured":"Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord. 2002;17(6):1318\u201320.","journal-title":"Mov Disord"},{"key":"14_CR174","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/mds.21730","volume":"22","author":"TR Thomsen","year":"2007","unstructured":"Thomsen TR, Galpern WR, Asante A, Arenovich T, Fox SH. Ipratropium bromide spray as treatment for sialorrhea in Parkinson\u2019s disease. Mov Disord. 2007;22:2268\u201373.","journal-title":"Mov Disord"},{"issue":"2","key":"14_CR175","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.23929","volume":"27","author":"R Chinnapongse","year":"2012","unstructured":"Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson\u2019s disease: a prospective double-blind trial. Mov Disord. 2012;27(2):219\u201326.","journal-title":"Mov Disord"},{"issue":"1","key":"14_CR176","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","volume":"62","author":"WG Ondo","year":"2004","unstructured":"Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson\u2019s disease. Neurology. 2004;62(1):37\u201340.","journal-title":"Neurology"},{"issue":"4","key":"14_CR177","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00415-009-0085-1","volume":"256","author":"G Lagalla","year":"2009","unstructured":"Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson\u2019s disease-related drooling. J Neurol. 2009;256(4):563\u20137.","journal-title":"J Neurol"},{"issue":"5","key":"14_CR178","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/mds.20793","volume":"21","author":"G Lagalla","year":"2006","unstructured":"Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2006;21(5):704\u20137.","journal-title":"Mov Disord"},{"issue":"4","key":"14_CR179","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/mds.870050404","volume":"5","author":"SA Factor","year":"1990","unstructured":"Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson\u2019s disease. Mov Disord. 1990;5(4):280\u20135.","journal-title":"Mov Disord"},{"issue":"7","key":"14_CR180","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1474-4422(06)70476-8","volume":"5","author":"A Iranzo","year":"2006","unstructured":"Iranzo A, Milonuevo JL, Santamaria J, Serradell M, Mart\u00ed MJ, Valldeoriola F, Tolosa E. Rapid-eye-movement sleep behavior disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006;5(7):572\u20137.","journal-title":"Lancet Neurol"},{"issue":"2","key":"14_CR181","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1212\/01.wnl.0000168864.97813.e0","volume":"65","author":"A Iranzo","year":"2005","unstructured":"Iranzo A, Santamar\u00eda J, Rye DB, Valldeoriola F, Mart\u00ed MJ, Mu\u00f1oz E, Vilaseca I, Tolosa E. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology. 2005;65(2):247\u201352.","journal-title":"Neurology"},{"key":"14_CR182","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/brain\/123.2.331","volume":"123","author":"EJ Olson","year":"2000","unstructured":"Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behavior disorder: demographic, clinical, and laboratory findings in 93 cases. Brain. 2000;123:331\u20139.","journal-title":"Brain"},{"issue":"10","key":"14_CR183","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/WNL.61.10.1418","volume":"61","author":"ML Fantini","year":"2003","unstructured":"Fantini ML, Gagnon JF, Filipini D, Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology. 2003;61(10):1418\u201320.","journal-title":"Neurology"},{"issue":"5","key":"14_CR184","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.sleep.2006.03.018","volume":"7","author":"MH Schmidt","year":"2006","unstructured":"Schmidt MH, Koshal VB, Schmidt HS. Use of pramipexole in REM sleep behavior disorder: results from a case series. Sleep Med. 2006;7(5):418\u201323.","journal-title":"Sleep Med"},{"key":"14_CR185","first-page":"1418","volume":"31","author":"H Kumru","year":"2008","unstructured":"Kumru H, Iranzo A, Carrasco E, Valldeoriola F, Marti MJ, Santamaria J, Tolosa E. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson\u2019s disease. Sleep. 2008;31:1418\u201321.","journal-title":"Sleep"},{"issue":"2","key":"14_CR186","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/sleep\/27.2.317","volume":"27","author":"JW Winkelman","year":"2004","unstructured":"Winkelman JW, James L. Serotoninergic antidepressants are associated with REM sleep without atonia. Sleep. 2004;27(2):317\u201321.","journal-title":"Sleep"},{"issue":"3","key":"14_CR187","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.58.3.465","volume":"58","author":"EK Tan","year":"2002","unstructured":"Tan EK, Lum SY, Fook-Chong SM, Teoh ML, Yih Y, Tan L, Tan A, Wong MC. Evaluation of somnolence in Parkinson\u2019s disease: comparison with age- and sex-matched controls. Neurology. 2002;58(3):465\u20138.","journal-title":"Neurology"},{"key":"14_CR188","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/sj.npp.1300250","volume":"28","author":"B H\u00f6gl","year":"2003","unstructured":"H\u00f6gl B, Rothdach A, Wetter TC, Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning function in patients with Parkinson\u2019s disease. Neuropsychopharmacology. 2003;28:866\u201370.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"14_CR189","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1468-1331.2006.01262.x","volume":"13","author":"JJ Ferreira","year":"2006","unstructured":"Ferreira JJ, Desboeuf K, Galitzky M, Thalamas C, Brefel-Courbon C, Fabre N, Senard JM, Montastruc JL, Sampaio C, Rascol O. Sleep disruption, daytime somnolence and \u2018sleep attacks\u2019 in Parkinson\u2019s disease: a clinical survey in PD patients and age matched healthy volunteers. Eur J Neurol. 2006;13(3):209\u201314.","journal-title":"Eur J Neurol"},{"issue":"3","key":"14_CR190","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00002826-200105000-00013","volume":"24","author":"JL Montastruc","year":"2001","unstructured":"Montastruc JL, Brefel-Courbon C, Senard JM, Bagheri H, Ferreira J, Rascol O, Lapeyre-Mestre M. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Neuropharmacology. 2001;24(3):181\u20133.","journal-title":"Neuropharmacology"},{"issue":"4","key":"14_CR191","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.287.4.455","volume":"287","author":"DE Hosborn","year":"2002","unstructured":"Hosborn DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson\u2019s disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002;287(4):455\u201363.","journal-title":"JAMA"},{"issue":"6","key":"14_CR192","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mds.10417","volume":"18","author":"S Paus","year":"2003","unstructured":"Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson\u2019s disease. Mov Disord. 2003;18(6):659\u201367.","journal-title":"Mov Disord"},{"issue":"6","key":"14_CR193","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.10429","volume":"18","author":"MA Brodsky","year":"2003","unstructured":"Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson\u2019s disease: a controlled study. Mov Disord. 2003;18(6):668\u201372.","journal-title":"Mov Disord"},{"issue":"11","key":"14_CR194","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/mds.20163","volume":"19","author":"Y K\u00f6rner","year":"2004","unstructured":"K\u00f6rner Y, Meindorfner C, M\u00f6ller JC, Stiasny-Kolster K, Haja D, Cassel W, Oertel WH, Kr\u00fcger HP. Predictors of sudden onset sleep in Parkinson\u2019s disease. Mov Disord. 2004;19(11):298\u2013305.","journal-title":"Mov Disord"},{"issue":"8","key":"14_CR195","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/sleep\/25.8.62","volume":"25","author":"B H\u00f6gl","year":"2002","unstructured":"H\u00f6gl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K, Ulmer H, Wenning G, Poewe W. Modafinil for the treatment of daytime sleepiness in Parkinson\u2019s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905\u20139.","journal-title":"Sleep"},{"issue":"3","key":"14_CR196","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mds.10390","volume":"18","author":"CH Adler","year":"2003","unstructured":"Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson\u2019s disease. Mov Disord. 2003;18(3):287\u201393.","journal-title":"Mov Disord"},{"issue":"12","key":"14_CR197","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/jnnp.2005.065870","volume":"76","author":"WG Ondo","year":"2005","unstructured":"Ondo WG, Fayle R, Atassi F, JanKovic J. Modafinil for daytime somnolence in Parkinson\u2019s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"14","key":"14_CR198","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/mds.21656","volume":"22","author":"DA Mendon\u00e7a","year":"2007","unstructured":"Mendon\u00e7a DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson\u2019s disease: a randomized controlled trail. Mov Disord. 2007;22(14):2070\u20136.","journal-title":"Mov Disord"}],"container-title":["Movement Disorders Curricula"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-7091-1628-9_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T23:52:19Z","timestamp":1568850739000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-7091-1628-9_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783709116272","9783709116289"],"references-count":198,"URL":"https:\/\/doi.org\/10.1007\/978-3-7091-1628-9_14","relation":{},"subject":[],"published":{"date-parts":[[2017]]}}}